The discovery and characterization of ML218: A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease

Zixiu Xiang, Analisa D. Thompson, John T. Brogan, Michael L. Schulte, Bruce J. Melancon, Debbie Mi, L. Michelle Lewis, Bende Zou, Liya Yang, Ryan Morrison, Tammy Santomango, Frank Byers, Katrina Brewer, Jonathan S. Aldrich, Haibo Yu, Eric S. Dawson, Min Li, Owen McManus, Carrie K. Jones, J. Scott DanielsCorey R. Hopkins, Ximin Simon Xie, P. Jeffrey Conn, C. David Weaver, Craig W. Lindsley

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

T-Type Ca 2+ channel inhibitors hold tremendous therapeutic potential for the treatment of pain, epilepsy, sleep disorders, essential tremor, and other neurological disorders; however, a lack of truly selective tools has hindered basic research, and selective tools from the pharmaceutical industry are potentially burdened with intellectual property (IP) constraints. Thus, an MLPCN high-throughput screen (HTS) was conducted to identify novel T-type Ca 2+ channel inhibitors free from IP constraints, and freely available through the MLPCN, for use by the biomedical community to study T-type Ca 2+ channels. While the HTS provided numerous hits, these compounds could not be optimized to the required level of potency to be appropriate tool compounds. Therefore, a scaffold hopping approach, guided by SurflexSim, ultimately afforded ML218 (CID 45115620), a selective T-type Ca 2+ (Ca v3.1, Ca v3.2, Ca v3.3) inhibitor (Ca v3.2, IC 50 = 150 nM in Ca 2+ flux; Ca v3.2 IC 50 = 310 nM; and Ca v3.3 IC 50 = 270 nM, respectively in patch clamp electrophysiology) with good DMPK properties, acceptable in vivo rat PK, and excellent brain levels. Electrophysiology studies in subthalamic nucleus (STN) neurons demonstrated robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. Based on the basal ganglia circuitry in Parkinson’s disease (PD), the effects of ML218 in STN neurons suggest a therapeutic role for T-type Ca 2+ channel inhibitors, and ML218 was found to be orally efficacious in haloperidol-induced catalepsy, a preclinical PD model, with comparable efficacy to an A 2A antagonist, a clinically validated PD target. ML218 proves to be a powerful new probe to study T-type Ca 2+ function in vitro and in vivo, and freely available.

Original languageEnglish (US)
Pages (from-to)730-742
Number of pages13
JournalACS Chemical Neuroscience
Volume2
Issue number12
DOIs
StatePublished - Dec 21 2011

Fingerprint

T-Type Calcium Channels
Subthalamic Nucleus
Intellectual Property
Neurons
Electrophysiology
Parkinson Disease
Rodentia
Intellectual property
Throughput
Essential Tremor
Catalepsy
Clamping devices
Drug Industry
Haloperidol
Basal Ganglia
Nervous System Diseases
Scaffolds
Rats
Epilepsy
Brain

Keywords

  • Parkinson's disease
  • T-Type calcium channel
  • electrophysiology
  • inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

The discovery and characterization of ML218 : A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease. / Xiang, Zixiu; Thompson, Analisa D.; Brogan, John T.; Schulte, Michael L.; Melancon, Bruce J.; Mi, Debbie; Lewis, L. Michelle; Zou, Bende; Yang, Liya; Morrison, Ryan; Santomango, Tammy; Byers, Frank; Brewer, Katrina; Aldrich, Jonathan S.; Yu, Haibo; Dawson, Eric S.; Li, Min; McManus, Owen; Jones, Carrie K.; Daniels, J. Scott; Hopkins, Corey R.; Xie, Ximin Simon; Conn, P. Jeffrey; Weaver, C. David; Lindsley, Craig W.

In: ACS Chemical Neuroscience, Vol. 2, No. 12, 21.12.2011, p. 730-742.

Research output: Contribution to journalArticle

Xiang, Z, Thompson, AD, Brogan, JT, Schulte, ML, Melancon, BJ, Mi, D, Lewis, LM, Zou, B, Yang, L, Morrison, R, Santomango, T, Byers, F, Brewer, K, Aldrich, JS, Yu, H, Dawson, ES, Li, M, McManus, O, Jones, CK, Daniels, JS, Hopkins, CR, Xie, XS, Conn, PJ, Weaver, CD & Lindsley, CW 2011, 'The discovery and characterization of ML218: A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease', ACS Chemical Neuroscience, vol. 2, no. 12, pp. 730-742. https://doi.org/10.1021/cn200090z
Xiang, Zixiu ; Thompson, Analisa D. ; Brogan, John T. ; Schulte, Michael L. ; Melancon, Bruce J. ; Mi, Debbie ; Lewis, L. Michelle ; Zou, Bende ; Yang, Liya ; Morrison, Ryan ; Santomango, Tammy ; Byers, Frank ; Brewer, Katrina ; Aldrich, Jonathan S. ; Yu, Haibo ; Dawson, Eric S. ; Li, Min ; McManus, Owen ; Jones, Carrie K. ; Daniels, J. Scott ; Hopkins, Corey R. ; Xie, Ximin Simon ; Conn, P. Jeffrey ; Weaver, C. David ; Lindsley, Craig W. / The discovery and characterization of ML218 : A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease. In: ACS Chemical Neuroscience. 2011 ; Vol. 2, No. 12. pp. 730-742.
@article{efec3deee031496aafc3f0e269d55b97,
title = "The discovery and characterization of ML218: A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease",
abstract = "T-Type Ca 2+ channel inhibitors hold tremendous therapeutic potential for the treatment of pain, epilepsy, sleep disorders, essential tremor, and other neurological disorders; however, a lack of truly selective tools has hindered basic research, and selective tools from the pharmaceutical industry are potentially burdened with intellectual property (IP) constraints. Thus, an MLPCN high-throughput screen (HTS) was conducted to identify novel T-type Ca 2+ channel inhibitors free from IP constraints, and freely available through the MLPCN, for use by the biomedical community to study T-type Ca 2+ channels. While the HTS provided numerous hits, these compounds could not be optimized to the required level of potency to be appropriate tool compounds. Therefore, a scaffold hopping approach, guided by SurflexSim, ultimately afforded ML218 (CID 45115620), a selective T-type Ca 2+ (Ca v3.1, Ca v3.2, Ca v3.3) inhibitor (Ca v3.2, IC 50 = 150 nM in Ca 2+ flux; Ca v3.2 IC 50 = 310 nM; and Ca v3.3 IC 50 = 270 nM, respectively in patch clamp electrophysiology) with good DMPK properties, acceptable in vivo rat PK, and excellent brain levels. Electrophysiology studies in subthalamic nucleus (STN) neurons demonstrated robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. Based on the basal ganglia circuitry in Parkinson{\^a}€™s disease (PD), the effects of ML218 in STN neurons suggest a therapeutic role for T-type Ca 2+ channel inhibitors, and ML218 was found to be orally efficacious in haloperidol-induced catalepsy, a preclinical PD model, with comparable efficacy to an A 2A antagonist, a clinically validated PD target. ML218 proves to be a powerful new probe to study T-type Ca 2+ function in vitro and in vivo, and freely available.",
keywords = "Parkinson's disease, T-Type calcium channel, electrophysiology, inhibitor",
author = "Zixiu Xiang and Thompson, {Analisa D.} and Brogan, {John T.} and Schulte, {Michael L.} and Melancon, {Bruce J.} and Debbie Mi and Lewis, {L. Michelle} and Bende Zou and Liya Yang and Ryan Morrison and Tammy Santomango and Frank Byers and Katrina Brewer and Aldrich, {Jonathan S.} and Haibo Yu and Dawson, {Eric S.} and Min Li and Owen McManus and Jones, {Carrie K.} and Daniels, {J. Scott} and Hopkins, {Corey R.} and Xie, {Ximin Simon} and Conn, {P. Jeffrey} and Weaver, {C. David} and Lindsley, {Craig W.}",
year = "2011",
month = "12",
day = "21",
doi = "10.1021/cn200090z",
language = "English (US)",
volume = "2",
pages = "730--742",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - The discovery and characterization of ML218

T2 - A novel, centrally active T-Type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's disease

AU - Xiang, Zixiu

AU - Thompson, Analisa D.

AU - Brogan, John T.

AU - Schulte, Michael L.

AU - Melancon, Bruce J.

AU - Mi, Debbie

AU - Lewis, L. Michelle

AU - Zou, Bende

AU - Yang, Liya

AU - Morrison, Ryan

AU - Santomango, Tammy

AU - Byers, Frank

AU - Brewer, Katrina

AU - Aldrich, Jonathan S.

AU - Yu, Haibo

AU - Dawson, Eric S.

AU - Li, Min

AU - McManus, Owen

AU - Jones, Carrie K.

AU - Daniels, J. Scott

AU - Hopkins, Corey R.

AU - Xie, Ximin Simon

AU - Conn, P. Jeffrey

AU - Weaver, C. David

AU - Lindsley, Craig W.

PY - 2011/12/21

Y1 - 2011/12/21

N2 - T-Type Ca 2+ channel inhibitors hold tremendous therapeutic potential for the treatment of pain, epilepsy, sleep disorders, essential tremor, and other neurological disorders; however, a lack of truly selective tools has hindered basic research, and selective tools from the pharmaceutical industry are potentially burdened with intellectual property (IP) constraints. Thus, an MLPCN high-throughput screen (HTS) was conducted to identify novel T-type Ca 2+ channel inhibitors free from IP constraints, and freely available through the MLPCN, for use by the biomedical community to study T-type Ca 2+ channels. While the HTS provided numerous hits, these compounds could not be optimized to the required level of potency to be appropriate tool compounds. Therefore, a scaffold hopping approach, guided by SurflexSim, ultimately afforded ML218 (CID 45115620), a selective T-type Ca 2+ (Ca v3.1, Ca v3.2, Ca v3.3) inhibitor (Ca v3.2, IC 50 = 150 nM in Ca 2+ flux; Ca v3.2 IC 50 = 310 nM; and Ca v3.3 IC 50 = 270 nM, respectively in patch clamp electrophysiology) with good DMPK properties, acceptable in vivo rat PK, and excellent brain levels. Electrophysiology studies in subthalamic nucleus (STN) neurons demonstrated robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. Based on the basal ganglia circuitry in Parkinson’s disease (PD), the effects of ML218 in STN neurons suggest a therapeutic role for T-type Ca 2+ channel inhibitors, and ML218 was found to be orally efficacious in haloperidol-induced catalepsy, a preclinical PD model, with comparable efficacy to an A 2A antagonist, a clinically validated PD target. ML218 proves to be a powerful new probe to study T-type Ca 2+ function in vitro and in vivo, and freely available.

AB - T-Type Ca 2+ channel inhibitors hold tremendous therapeutic potential for the treatment of pain, epilepsy, sleep disorders, essential tremor, and other neurological disorders; however, a lack of truly selective tools has hindered basic research, and selective tools from the pharmaceutical industry are potentially burdened with intellectual property (IP) constraints. Thus, an MLPCN high-throughput screen (HTS) was conducted to identify novel T-type Ca 2+ channel inhibitors free from IP constraints, and freely available through the MLPCN, for use by the biomedical community to study T-type Ca 2+ channels. While the HTS provided numerous hits, these compounds could not be optimized to the required level of potency to be appropriate tool compounds. Therefore, a scaffold hopping approach, guided by SurflexSim, ultimately afforded ML218 (CID 45115620), a selective T-type Ca 2+ (Ca v3.1, Ca v3.2, Ca v3.3) inhibitor (Ca v3.2, IC 50 = 150 nM in Ca 2+ flux; Ca v3.2 IC 50 = 310 nM; and Ca v3.3 IC 50 = 270 nM, respectively in patch clamp electrophysiology) with good DMPK properties, acceptable in vivo rat PK, and excellent brain levels. Electrophysiology studies in subthalamic nucleus (STN) neurons demonstrated robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. Based on the basal ganglia circuitry in Parkinson’s disease (PD), the effects of ML218 in STN neurons suggest a therapeutic role for T-type Ca 2+ channel inhibitors, and ML218 was found to be orally efficacious in haloperidol-induced catalepsy, a preclinical PD model, with comparable efficacy to an A 2A antagonist, a clinically validated PD target. ML218 proves to be a powerful new probe to study T-type Ca 2+ function in vitro and in vivo, and freely available.

KW - Parkinson's disease

KW - T-Type calcium channel

KW - electrophysiology

KW - inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84555194740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555194740&partnerID=8YFLogxK

U2 - 10.1021/cn200090z

DO - 10.1021/cn200090z

M3 - Article

C2 - 22368764

AN - SCOPUS:84555194740

VL - 2

SP - 730

EP - 742

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 12

ER -